Stockscreener 앱 받기
21.39
0.38%
0.08
시간 외 거래:
21.37
-0.02
-0.09%
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Glazer Capital (NASDAQ: DAWN) reports 5.6M-share, 5.44% stake - Stock Titan
Take Profit: Is Day One Biopharmaceuticals Inc a strong growth stockStock Surge & AI Driven Stock Reports - baoquankhu1.vn
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration - MSN
Trading Action: What are the future prospects of Day One Biopharmaceuticals IncRisk Management & AI Forecasted Stock Moves - baoquankhu1.vn
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
(DAWN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Algert Global LLC Buys 411,000 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? - Sahm
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - Sahm
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
symbol__ Stock Quote Price and Forecast - CNN
HC Wainwright & Co. downgrades Day One Biopharmaceuticals (DAWN) - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
EDGAR Filing Documents for 0001193125-24-108544 - SEC.gov
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition - Investing.com Canada
Servier to acquire Day One Biopharmaceuticals for $2.5 billion - Investing.com Nigeria
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Day One Biopharma : DAWN - 24/7 Wall St.
Day One Biopharmaceutical (DAWN) Downgraded to Neutral by HC Wai - GuruFocus
Day One (DAWN) soars 100% on $2.5-billion merger - MSN
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - Finviz
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now - TechStock²
Day One (DAWN) climbs to 3-year high on $2.5-billion merger - MSN
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - The Globe and Mail
DAWN Stock Downgraded by Wedbush with Price Target Adjustment | - GuruFocus
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen - MarketBeat
Servier acquires International Biotech's Day One for USD2.5 billion - marketscreener.com
Day One Biopharma Earnings Call Highlights Ojemda Surge - The Globe and Mail
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Top Small Cap Stocks To Add to Your WatchlistMarch 7th - MarketBeat
Key deals this week: Diana Shipping, Day One Biopharmaceuticals, Hudbay Minerals and more - Seeking Alpha
Pharmaceutical Stocks To ResearchMarch 7th - MarketBeat
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
Knott David M Jr Grows Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to "Hold" at Wedbush - MarketBeat
Servier to acquire Day One Biopharmaceuticals for $2.5 billion By Investing.com - Investing.com Canada
Day One Biopharmaceuticals stock hits 52-week high at 21.12 USD - Investing.com Canada
Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger - Yahoo Finance
Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal - International Business Times Australia
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - ET Pharma
Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion - Pulse 2.0
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc.DAWN - Business Wire
User - The Chronicle-Journal
Day One Biopharmaceuticals, Inc. (DAWN): A Hold Rating Amid Emerging Potential - 富途牛牛
DAWN: Cowen Downgrades Day One Biopharmaceuticals to Hold March 2026 - Meyka
1.20%
0.06%
자본화:
|
볼륨(24시간):